Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Role of lamin A/C on dendritic cell function in antiviral immunity.

  • Herrero-Fernández, Beatriz
  • Ortega-Zapero, Marina
  • Gómez-Bris, Raquel
  • Sáez, Angela
  • Iborra, Salvador
  • Zorita, Virginia
  • Quintas, Ana
  • Vázquez, Enrique
  • Dopazo, Ana
  • Sánchez-Madrid, Francisco
  • Arribas, Silvia Magdalena
  • González-Granado, Jose Maria
Dendritic cells (DCs) play a crucial role in orchestrating immune responses, particularly in promoting IFNγ-producing-CD8 cytotoxic T lymphocytes (CTLs) and IFNγ-producing-CD4 T helper 1 (Th1) cells, which are essential for defending against viral infections. Additionally, the nuclear envelope protein lamin A/C has been implicated in T cell immunity. Nevertheless, the intricate interplay between innate and adaptive immunity in response to viral infections, particularly the role of lamin A/C in DC functions within this context, remains poorly understood. In this study, we demonstrate that mice lacking lamin A/C in myeloid LysM promoter-expressing cells exhibit a reduced capacity to induce Th1 and CD8 CTL responses, leading to impaired clearance of acute primary Vaccinia virus (VACV) infection. Remarkably, in vitro-generated granulocyte macrophage colony-stimulating factor bone marrow-derived DCs (GM-CSF BMDCs) show high levels of lamin A/C. Lamin A/C absence on GM-CSF BMDCs does not affect the expression of costimulatory molecules on the cell membrane but it reduces the cellular ability to form immunological synapses with naïve CD4 T cells. Lamin A/C deletion induces alterations in NFκB nuclear localization, thereby influencing NF-κB-dependent transcription. Furthermore, lamin A/C ablation modifies the gene accessibility of BMDCs, predisposing these cells to mount a less effective antiviral response upon TLR stimulation. This study highlights the critical role of DCs in interacting with CD4 T cells during antiviral responses and proposes some mechanisms through which lamin A/C may modulate DC function via gene accessibility and transcriptional regulation.
Repisalud
Publication Artículo científico (JournalArticle)

Lamin A/C and the Immune System: One Intermediate Filament, Many Faces.

  • Saez, Angela
  • Herrero-Fernandez, Beatriz
  • Gomez-Bris, Raquel
  • Somovilla-Crespo, Beatriz
  • Rius, Cristina
  • Gonzalez-Granado, Jose Maria
Nuclear envelope lamin A/C proteins are a major component of the mammalian nuclear lamina, a dense fibrous protein meshwork located in the nuclear interior. Lamin A/C proteins regulate nuclear mechanics and structure and control cellular signaling, gene transcription, epigenetic regulation, cell cycle progression, cell differentiation, and cell migration. The immune system is composed of the innate and adaptive branches. Innate immunity is mediated by myeloid cells such as neutrophils, macrophages, and dendritic cells. These cells produce a rapid and nonspecific response through phagocytosis, cytokine production, and complement activation, as well as activating adaptive immunity. Specific adaptive immunity is activated by antigen presentation by antigen presenting cells (APCs) and the cytokine microenvironment, and is mainly mediated by the cellular functions of T cells and the production of antibodies by B cells. Unlike most cell types, immune cells regulate their lamin A/C protein expression relatively rapidly to exert their functions, with expression increasing in macrophages, reducing in neutrophils, and increasing transiently in T cells. In this review, we discuss and summarize studies that have addressed the role played by lamin A/C in the functions of innate and adaptive immune cells in the context of human inflammatory and autoimmune diseases, pathogen infections, and cancer.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

  • Cortés Vicente, Elena
  • Álvarez Velasco, Rodrigo
  • Pla Junca, Francesc
  • Rojas García, Ricard
  • Paradas, Carmen
  • Sevilla, Teresa
  • Casasnovas, Carlos
  • Gómez Caravaca, María Teresa
  • Pardo Fernández, Julio
  • Ramos Fransi, Alba
  • Pelayo Negro, Ana Lara
  • Gutiérrez Gutiérrez, G.
  • Turón Sans, Janina
  • López de Munain Arregui, Adolfo José
  • Guerrero Sola, Antonio
  • Jericó, Ivonne
  • Martín, María Asunción
  • Mendoza, María Dolores
  • Morís de la Tassa, G.
  • Vélez Gómez, Beatriz
  • García Sobrino, Tania
  • Pascual Goñi, Elba
  • Reyes Leiva, David
  • Illa, Isabel
  • Gallardo, Eduard
[EN] Objective: To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. Methods: This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were considered refractory when their MG Foundation of America post-interventional status (MGFA-PIS) was unchanged or worse after corticosteroids and two or more other immunosuppressive agents. Clinical and immunologic characteristics of drug-refractory patients, efficiency and toxicity of drugs used, and outcome (MGFA-PIS) at end of follow-up were studied. Results: We included 990 patients from 15 hospitals. Eighty-four patients (68 of 842 anti-acetylcholine receptor [AChR], 5 of 26 anti-muscle-specific tyrosine kinase [MusK], 10 of 120 seronegative, and 1 of 2 double-seropositive patients) were drug refractory. Drug-refractory patients were more frequently women (p < 0.0001), younger at onset (p < 0.0001), and anti-MuSK positive (p = 0.037). Moreover, they more frequently presented a generalized form of the disease, bulbar symptoms, and life-threatening events (p < 0.0001; p = 0.018; and p = 0.002, respectively) than non-drug-refractory patients. Mean follow-up was 9.8 years (SD 4.5). Twenty-four (50%) refractory patients had side effects to one or more of the drugs. At the end of follow-up, 42.9% of drug-refractory patients (42.6% of anti-AChR, 100% of anti-MuSK, and 10% of seronegative patients) and 79.8% of non-drug-refractory patients (p < 0.0001) achieved remission or had minimal manifestations. Eighty percent of drug-refractory-seronegative patients did not respond to any drug tested. Interpretation: In this study, 8.5% of MG patients were drug-refractory. New more specific drugs are needed to treat drug-refractory MG patients., This work was funded by the Instituto de Salud Carlos III through the project PI19/01774 (cofunded by the European Union ERDF), PI I. Illa and E. Gallardo. E. Cortes-Vicente was supported by a Juan Rodes grant (JR19/00037) from the Fondo de Investigacion en Salud, Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, "A way to make Europe"/"Investing in your future"), Ministry of Health (Spain). R. Alvarez-Velasco was supported by grant SLT008/18/00207 from the Health Research and Innovation Strategic Plan (PERIS). The NMD-ES Project and F. PlaJunca (data curator) are partially funded by the Centro de Investigacion Biomedica en Red de Enfsermedades Raras (CIBERER).
Docta Complutense
Publication Artículo científico (JournalArticle)

Role of Lamin A/C on dendritic cell function in antiviral immunity

  • Herrero-Fernandez, Beatriz
  • Gómez Bris, Raquel
  • Ortega-Zapero, Marina
  • Saez, Angela
  • Iborra Martín, Salvador
  • Zorita, Virginia
  • Quintas, Ana
  • Vazquez, Enrique
  • Dopazo, Ana
  • Sánchez Madrid, Francisco
  • Arribas, Silvia Magdalena
  • González Granado, José María
Dendritic cells (DCs) play a crucial role in orchestrating immune responses, particularly in promoting IFNγ-producing-CD8 cytotoxic T lymphocytes (CTLs) and IFNγ-producing-CD4 T helper 1 (Th1) cells, which are essential for defending against viral infections. Additionally, the nuclear envelope protein lamin A/C has been implicated in T cell immunity. Nevertheless, the intricate interplay between innate and adaptive immunity in response to viral infections, particularly the role of lamin A/C in DC functions within this context, remains poorly understood. In this study, we demonstrate that mice lacking lamin A/C in myeloid LysM promoter-expressing cells exhibit a reduced capacity to induce Th1 and CD8 CTL responses, leading to impaired clearance of acute primary Vaccinia virus (VACV) infection. Remarkably, in vitro-generated granulocyte macrophage colony-stimulating factor bone marrow-derived DCs (GM-CSF BMDCs) show high levels of lamin A/C. Lamin A/C absence on GM-CSF BMDCs does not affect the expression of costimulatory molecules on the cell membrane but it reduces the cellular ability to form immunological synapses with naïve CD4 T cells. Lamin A/C deletion induces alterations in NFκB nuclear localization, thereby influencing NF-κB-dependent transcription. Furthermore, lamin A/C ablation modifies the gene accessibility of BMDCs, predisposing these cells to mount a less effective antiviral response upon TLR stimulation. This study highlights the critical role of DCs in interacting with CD4 T cells during antiviral responses and proposes some mechanisms through which lamin A/C may modulate DC function via gene accessibility and transcriptional regulation
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Drug-refractory myasthenia gravis, Clinical characteristics, treatments, and outcome

  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Álvarez Velasco, Rodrigo|||0000-0002-4743-7205
  • Pla-Junca, Francesc
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Paradas, Carmen|||0000-0002-6917-2236
  • Sevilla, Teresa|||0000-0003-4716-2667
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Gómez-Caravaca, María Teresa
  • Pardo, Julio|||0000-0001-8807-1310
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Pelayo-Negro, Ana Lara
  • Gutiérrez-Gutiérrez, Gerardo
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Guerrero Sola, Antonio
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Martín, María Asunción
  • Mendoza, María Dolores
  • Morís, Germán|||0000-0001-7608-2194
  • Vélez-Gómez, Beatriz|||0000-0001-5796-5872
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were considered refractory when their MG Foundation of America post-interventional status (MGFA-PIS) was unchanged or worse after corticosteroids and two or more other immunosuppressive agents. Clinical and immunologic characteristics of drug-refractory patients, efficiency and toxicity of drugs used, and outcome (MGFA-PIS) at end of follow-up were studied. We included 990 patients from 15 hospitals. Eighty-four patients (68 of 842 anti-acetylcholine receptor [AChR], 5 of 26 anti-muscle-specific tyrosine kinase [MusK], 10 of 120 seronegative, and 1 of 2 double-seropositive patients) were drug refractory. Drug-refractory patients were more frequently women (p < 0.0001), younger at onset (p < 0.0001), and anti-MuSK positive (p = 0.037). Moreover, they more frequently presented a generalized form of the disease, bulbar symptoms, and life-threatening events (p < 0.0001; p = 0.018; and p = 0.002, respectively) than non-drug-refractory patients. Mean follow-up was 9.8 years (SD 4.5). Twenty-four (50%) refractory patients had side effects to one or more of the drugs. At the end of follow-up, 42.9% of drug-refractory patients (42.6% of anti-AChR, 100% of anti-MuSK, and 10% of seronegative patients) and 79.8% of non-drug-refractory patients (p < 0.0001) achieved remission or had minimal manifestations. Eighty percent of drug-refractory-seronegative patients did not respond to any drug tested. In this study, 8.5% of MG patients were drug-refractory. New more specific drugs are needed to treat drug-refractory MG patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis

  • Álvarez Velasco, Rodrigo|||0000-0002-4743-7205
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • El Bounasri, Shaima|||0000-0003-0384-1633
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Trujillo Reyes, Juan Carlos|||0000-0002-3370-0869
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
Myasthenia gravis (MG) is an autoimmune disease associated with comorbid thymoma in 10%-15% of cases. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) expressed by T cells downregulates T-cell-mediated immune response. Polymorphisms in the CTLA4 gene have been associated with the development of MG. In this context, we aimed to determine whether CTLA4 expression in the thymoma differs between patients with and without MG and whether CTLA4 gene polymorphisms are associated with these differences. This is a retrospective study of all patients, with and without MG, surgically treated at our institution for thymoma between January 2010 and December 2020. Ten samples were obtained from normal thymuses as controls. The number of CTLA4-positive cells in paraffin-embedded thymoma samples was determined by immunohistochemistry. The presence of follicular-center and regulatory T-cell lymphocytes was determined by immunohistochemistry (B-cell lymphoma [BCL]-6 expression) and double immunofluorescence-based staining of CD4-FOXP3, respectively. We evaluated the association between thymic expression of CTLA4 and the development of MG. We also determined the association between CTLA4 expression and various clinical and prognostic characteristics of MG. We sequenced the CTLA4 gene and evaluated possible associations between CTLA4 polymorphisms and thymic CTLA4 expression. Finally, we assessed the potential association between these polymorphisms and the risk of MG. Forty-one patients with thymoma were included. Of them, 23 had comorbid MG (56.1%). On average, patients with MG had fewer CTLA4-positive cells in the thymoma than non-MG patients: 69.3 cells/mm 2 (95% CIs: 39.6-99.1) vs 674.4 (276.0-1,024.0) cells/mm 2 ; p = 0.001 and vs controls (200.74 [57.9-343.6] cells/mm 2 ; p = 0.02). No between-group differences (MG vs non-MG) were observed in the number of cells positive for BCL6 or CD4-FOXP3. CTLA4 expression was not associated with differences in MG outcome or treatment refractoriness. Two polymorphisms were detected in the CTLA4 gene, rs231770 (n = 30 patients) and rs231775 (n = 17). MG was present in a similar proportion of patients for all genotypes. However, a nonsignificant trend toward a lower CTLA4-positive cell count was observed among carriers of the rs231775 polymorphism vs noncarriers: 77.9 cells/mm 2 (95% CI: -51.5 to 207.5) vs 343.3 cells/mm 2 (95% CI: 126.2-560.4). Reduced CTLA4 expression in thymoma may predispose to a higher risk of developing MG.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis

  • Reyes-Leiva, David|||0000-0001-6983-7130
  • López-Contreras, Joaquín|||0000-0002-3166-4016
  • Moga, Esther|||0000-0003-4264-6910
  • Pla-Juncà, Francesc|||0000-0002-4403-6297
  • Lynton-Pons, Elionor|||0000-0001-5375-7195
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Querol, Luis|||0000-0002-4289-8264
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Álvarez Velasco, Rodrigo|||0000-0002-4743-7205
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Illa, Ignacio
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
Evidence regarding the safety and efficacy of messenger RNA (mRNA) vaccines in patients with myasthenia gravis (MG) after immunosuppressive therapies is scarce. Our aim is to determine whether the mRNA-1273 vaccine is safe and able to induce humoral and cellular responses in patients with MG. We performed an observational, longitudinal, prospective study including 100 patients with MG of a referral center for MG in our country, conducted from April 2021 to November 2021 during the vaccination campaign. The mRNA-1273 vaccine was scheduled for all participants. Blood samples were collected before vaccination and 3 months after a second dose. Clinical changes in MG were measured using the MG activities of daily life score at baseline and 1 week after the first and second doses. A surveillance of all symptoms of coronavirus disease 2019 (COVID-19) was conducted throughout the study. Humoral and cellular immune responses after vaccination were assessed using a spike-antibody ELISA and interferon gamma release assay in plasma. The primary outcomes were clinically significant changes in MG symptoms after vaccination, adverse events (AEs), and seroconversion and T-cell immune response rates. Ninety-nine patients completed the full vaccination schedule, and 98 had 2 blood samples taken. A statistically significant worsening of symptoms was identified after the first and second doses of the mRNA-1273 vaccine, but this was not clinically relevant. Mild AEs occurred in 14 patients after the first dose and in 21 patients after the second dose. Eighty-seven patients developed a humoral response and 72 patients showed a T-cell response after vaccination. A combined therapy with prednisone and other immunosuppressive drugs correlated with a lower seroconversion ratio (OR = 5.97, 95% CI 1.46-24.09, p = 0.015) and a lower T-cell response ratio (OR = 2.83, 95% CI 1.13-7.13, p = 0.024). Our findings indicate that the mRNA vaccination against COVID-19 is safe in patients with MG and show no negative impact on the disease course. Patients achieved high humoral and cellular immune response levels. This study provides Class IV evidence that patients with MG receiving the mRNA-1273 vaccine did not show clinical worsening after vaccination and that most of the patients achieved high cellular or immune response levels.